256 related articles for article (PubMed ID: 15937544)
1. Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma.
Kaufman HL; Deraffele G; Mitcham J; Moroziewicz D; Cohen SM; Hurst-Wicker KS; Cheung K; Lee DS; Divito J; Voulo M; Donovan J; Dolan K; Manson K; Panicali D; Wang E; Hörig H; Marincola FM
J Clin Invest; 2005 Jul; 115(7):1903-12. PubMed ID: 15937544
[TBL] [Abstract][Full Text] [Related]
2. Local delivery of vaccinia virus expressing multiple costimulatory molecules for the treatment of established tumors.
Kaufman HL; Cohen S; Cheung K; DeRaffele G; Mitcham J; Moroziewicz D; Schlom J; Hesdorffer C
Hum Gene Ther; 2006 Feb; 17(2):239-44. PubMed ID: 16454657
[TBL] [Abstract][Full Text] [Related]
3. Phase I/II clinical trial of a nonreplicative vaccinia virus expressing multiple HLA-A0201-restricted tumor-associated epitopes and costimulatory molecules in metastatic melanoma patients.
Zajac P; Oertli D; Marti W; Adamina M; Bolli M; Guller U; Noppen C; Padovan E; Schultz-Thater E; Heberer M; Spagnoli G
Hum Gene Ther; 2003 Nov; 14(16):1497-510. PubMed ID: 14577912
[TBL] [Abstract][Full Text] [Related]
4. Rapid induction of specific cytotoxic T lymphocytes against melanoma-associated antigens by a recombinant vaccinia virus vector expressing multiple immunodominant epitopes and costimulatory molecules in vivo.
Oertli D; Marti WR; Zajac P; Noppen C; Kocher T; Padovan E; Adamina M; Schumacher R; Harder F; Heberer M; Spagnoli GC
Hum Gene Ther; 2002 Mar; 13(4):569-75. PubMed ID: 11874634
[TBL] [Abstract][Full Text] [Related]
5. Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination: a phase I trial in metastatic melanoma.
Di Nicola M; Carlo-Stella C; Mortarini R; Baldassari P; Guidetti A; Gallino GF; Del Vecchio M; Ravagnani F; Magni M; Chaplin P; Cascinelli N; Parmiani G; Gianni AM; Anichini A
Clin Cancer Res; 2004 Aug; 10(16):5381-90. PubMed ID: 15328176
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of nonreplicating recombinant vaccinia expressing HLA-A201 targeted or complete MART-1/Melan-A antigen.
Schütz A; Oertli D; Marti WR; Noppen C; Padovan E; Spagnoli GC; Heberer M; Zajac P
Cancer Gene Ther; 2001 Sep; 8(9):655-61. PubMed ID: 11593334
[TBL] [Abstract][Full Text] [Related]
7. Validation of a HLA-A2 tetramer flow cytometric method, IFNgamma real time RT-PCR, and IFNgamma ELISPOT for detection of immunologic response to gp100 and MelanA/MART-1 in melanoma patients.
Xu Y; Theobald V; Sung C; DePalma K; Atwater L; Seiger K; Perricone MA; Richards SM
J Transl Med; 2008 Oct; 6():61. PubMed ID: 18945350
[TBL] [Abstract][Full Text] [Related]
8. Enhanced generation of cytotoxic T lymphocytes using recombinant vaccinia virus expressing human tumor-associated antigens and B7 costimulatory molecules.
Zajac P; Schütz A; Oertli D; Noppen C; Schaefer C; Heberer M; Spagnoli GC; Marti WR
Cancer Res; 1998 Oct; 58(20):4567-71. PubMed ID: 9788602
[TBL] [Abstract][Full Text] [Related]
9. Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine.
Dangoor A; Lorigan P; Keilholz U; Schadendorf D; Harris A; Ottensmeier C; Smyth J; Hoffmann K; Anderson R; Cripps M; Schneider J; Hawkins R
Cancer Immunol Immunother; 2010 Jun; 59(6):863-73. PubMed ID: 20043222
[TBL] [Abstract][Full Text] [Related]
10. Induction of melanoma antigen-specific cytotoxic T lymphocytes in vitro by stimulation with B7-expressing human melanoma cell lines.
Fenton RG; Turcovski-Corrales SM; Taub DD
J Immunother; 1998 Mar; 21(2):95-108. PubMed ID: 9551360
[TBL] [Abstract][Full Text] [Related]
11. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors.
Di Pucchio T; Pilla L; Capone I; Ferrantini M; Montefiore E; Urbani F; Patuzzo R; Pennacchioli E; Santinami M; Cova A; Sovena G; Arienti F; Lombardo C; Lombardi A; Caporaso P; D'Atri S; Marchetti P; Bonmassar E; Parmiani G; Belardelli F; Rivoltini L
Cancer Res; 2006 May; 66(9):4943-51. PubMed ID: 16651452
[TBL] [Abstract][Full Text] [Related]
12. Dual expression of human leukocyte antigen molecules and the B7-1 costimulatory molecule (CD80) on human melanoma cells after particle-mediated gene transfer.
Albertini MR; Emler CA; Schell K; Tans KJ; King DM; Sheehy MJ
Cancer Gene Ther; 1996; 3(3):192-201. PubMed ID: 8725884
[TBL] [Abstract][Full Text] [Related]
13. Admixture of a recombinant vaccinia virus containing the gene for the costimulatory molecule B7 and a recombinant vaccinia virus containing a tumor-associated antigen gene results in enhanced specific T-cell responses and antitumor immunity.
Hodge JW; McLaughlin JP; Abrams SI; Shupert WL; Schlom J; Kantor JA
Cancer Res; 1995 Aug; 55(16):3598-603. PubMed ID: 7543017
[TBL] [Abstract][Full Text] [Related]
14. Selective responsiveness to common gamma chain cytokines in peripheral blood-derived cytotoxic T lymphocytes induced by Melan-A/MART-1(27-35)targeted active specific immunotherapy.
von Holzen U; Adamina M; Bolli M; Weber WP; Zajac P; Groeper C; Reschner A; Feder C; Schumacher R; Marti W; Oertli D; Heberer M; Spagnoli GC
Int J Cancer; 2005 Jun; 115(2):248-55. PubMed ID: 15688403
[TBL] [Abstract][Full Text] [Related]
15. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
16. Stringent allele/epitope requirements for MART-1/Melan A immunodominance: implications for peptide-based immunotherapy.
Bettinotti MP; Kim CJ; Lee KH; Roden M; Cormier JN; Panelli M; Parker KK; Marincola FM
J Immunol; 1998 Jul; 161(2):877-89. PubMed ID: 9670966
[TBL] [Abstract][Full Text] [Related]
17. Analysis of T-cell responses in metastatic melanoma patients vaccinated with dendritic cells pulsed with tumor lysates.
Griffioen M; Borghi M; Schrier PI; Osanto S; Schadendorf D
Cancer Immunol Immunother; 2004 Aug; 53(8):715-22. PubMed ID: 14997347
[TBL] [Abstract][Full Text] [Related]
18. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.
Choi KJ; Kim JH; Lee YS; Kim J; Suh BS; Kim H; Cho S; Sohn JH; Kim GE; Yun CO
Gene Ther; 2006 Jul; 13(13):1010-20. PubMed ID: 16525479
[TBL] [Abstract][Full Text] [Related]
19. Nonreplicating recombinant vaccinia virus expressing CD40 ligand enhances APC capacity to stimulate specific CD4+ and CD8+ T cell responses.
Feder-Mengus C; Schultz-Thater E; Oertli D; Marti WR; Heberer M; Spagnoli GC; Zajac P
Hum Gene Ther; 2005 Mar; 16(3):348-60. PubMed ID: 15812230
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of the intratumoral administration of recombinant canarypox viruses expressing B7.1 and interleukin 12 in patients with metastatic melanoma.
Triozzi PL; Allen KO; Carlisle RR; Craig M; LoBuglio AF; Conry RM
Clin Cancer Res; 2005 Jun; 11(11):4168-75. PubMed ID: 15930353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
